This Article Full Text Full Text (PDF) Supplementary Data Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Ibanez de Caceres, I. Articles by Cairns, P. Search for Related Content PubMed PubMed Citation Articles by Ibanez de Caceres, I. Articles by Cairns, P.

Identification of Novel Target Genes by an Epigenetic Reactivation Screen of Renal Cancer

Departments of ¹ Surgical Oncology and ² Pathology, Fox Chase Cancer Center, Philadelphia, Pennsylvania

Requests for reprints: Paul Cairns, Fox Chase Cancer Center, 333 Cottman Avenue, Philadelphia, PA 19111. Phone: 215-7285635; Fax: 215-7282487; E-mail: Paul.Cairns{at}fccc.edu.

Aberrant promoter hypermethylation is a common mechanism for inactivation of tumor suppressor genes in cancer cells. To generate a global profile of genes silenced by hypermethylation in renal cell cancer (RCC), we did an expression microarray-based analysis of genes reactivated in the 786-0, ACHN, HRC51, and HRC59 RCC lines after treatment with the demethylating drug 5-aza-2 deoxycytidine and histone deacetylation inhibiting drug trichostatin A. Between 111 to 170 genes were found to have at least 3-fold up-regulation of expression after treatment in each cell line. To establish the specificity of the screen for identification of genes, epigenetically silenced in cancer cells, we validated a subset of 12 up-regulated genes. Three genes (IGFBP1, IGFBP3, and COL1A1) showed promoter methylation in tumor DNA but were unmethylated in normal cell DNA. One gene (GDF15) was methylated in normal cells but more densely methylated in tumor cells. One gene (PLAU) showed cancer cell–specific methylation that did not correlate well with expression status. The remaining seven genes had unmethylated promoters, although at least one of these genes (TGM2) may be regulated by RASSF1A, which was methylated in the RCC lines. Thus, we were able to show that up-regulation of at least 6 of the 12 genes examined was due to epigenetic reactivation. The IGFBP1, IGFBP3, and COL1A1 gene promoter regions were found to be frequently methylated in primary renal cell tumors, and further study will provide insight into the biology of the disease and facilitate translational studies in renal cancer. (Cancer Res 2006; 66(10): 5021-8)

This article has been cited by other articles:

				S. Jogie-Brahim, D. Feldman, and Y. Oh Unraveling Insulin-Like Growth Factor Binding Protein-3 Actions in Human Disease Endocr. Rev., August 1, 2009; 30(5): 417 - 437. [Abstract] [Full Text] [PDF]

				K Revill, K J Dudley, R N Clayton, A M McNicol, and W E Farrell Loss of neuronatin expression is associated with promoter hypermethylation in pituitary adenoma Endocr. Relat. Cancer, June 1, 2009; 16(2): 537 - 548. [Abstract] [Full Text] [PDF]

				R. Humeniuk, P. J. Mishra, J. R. Bertino, and D. Banerjee Epigenetic reversal of acquired resistance to 5-fluorouracil treatment Mol. Cancer Ther., May 1, 2009; 8(5): 1045 - 1054. [Abstract] [Full Text] [PDF]

				E. Arai, S. Ushijima, H. Fujimoto, F. Hosoda, T. Shibata, T. Kondo, S. Yokoi, I. Imoto, J. Inazawa, S. Hirohashi, et al. Genome-wide DNA methylation profiles in both precancerous conditions and clear cell renal cell carcinomas are correlated with malignant potential and patient outcome Carcinogenesis, February 1, 2009; 30(2): 214 - 221. [Abstract] [Full Text] [PDF]

				K. J. Dudley, K. Revill, P. Whitby, R. N. Clayton, and W. E. Farrell Genome-Wide Analysis in a Murine Dnmt1 Knockdown Model Identifies Epigenetically Silenced Genes in Primary Human Pituitary Tumors Mol. Cancer Res., October 1, 2008; 6(10): 1567 - 1574. [Abstract] [Full Text] [PDF]

				G. Heller, W. M. Schmidt, B. Ziegler, S. Holzer, L. Mullauer, M. Bilban, C. C. Zielinski, J. Drach, and S. Zochbauer-Muller Genome-Wide Transcriptional Response to 5-Aza-2'-Deoxycytidine and Trichostatin A in Multiple Myeloma Cells Cancer Res., January 1, 2008; 68(1): 44 - 54. [Abstract] [Full Text] [PDF]

				J. Kagan, S. Srivastava, P. E. Barker, S. A. Belinsky, and P. Cairns Towards Clinical Application of Methylated DNA Sequences as Cancer Biomarkers: A Joint NCI's EDRN and NIST Workshop on Standards, Methods, Assays, Reagents and Tools Cancer Res., May 15, 2007; 67(10): 4545 - 4549. [Abstract] [Full Text] [PDF]